GALECTIN THERAPEUTICS INC (GALT) Stock Earnings & Estimates
NASDAQ:GALT - US3632252025 - Common Stock
3.98 USD
-0.18 (-4.33%)
3.98 USD
0 (0%)
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | N/A | N/A | ||||||||||||
| EBITDA YoY % growth | -15.42M | -20.07M -30.16% | -21.47M -6.98% | -16.25M 24.31% | -13.6M 16.31% | N/A | N/A | N/A | N/A | -38.039M | -42.396M -11.45% | N/A 13.15% | N/A -19.39% | N/A -11.14% | N/A | |
| EBIT YoY % growth | -15.43M | -20.08M -30.14% | -21.48M -6.97% | -16.25M 24.35% | -13.6M 16.31% | -13.44M 1.18% | -23.44M -74.40% | -30.18M -28.75% | -38.35M -27.07% | -38.072M 0.72% | -42.433M -11.45% | N/A 13.22% | N/A -19.39% | N/A -11.14% | N/A 712.43% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | -0.77 | -0.88 -14.29% | -0.75 14.77% | -0.49 34.67% | -0.38 22.45% | -0.43 -13.16% | -0.40 6.98% | -0.51 -27.50% | -0.65 -27.45% | -0.74 -13.85% | -0.76 -2.70% | N/A 34.24% | N/A 10.20% | N/A -11.36% | N/A |
All data in USD
| Q3 / 25 | Q4 / 25 | |
|---|---|---|
| EPS Q2Q % growth | -0.11 37.67% | -0.10 46.32% |
| Revenue Q2Q % growth | ||
| EBITDA Q2Q % growth | -5.61M 37.94% | -6.528M 47.32% |
| EBIT Q2Q % growth | -15.402M -69.89% | -17.136M -37.88% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q2 2025 Q2Q % growth | -0.12 40.00% | -0.16 | 0.04 | 26.47% |
| Q1 2025 Q2Q % growth | -0.15 21.05% | -0.20 | 0.05 | 26.47% |
| Q4 2024 Q2Q % growth | -0.19 -18.75% | -0.16 | -0.03 | -16.42% |
| Q3 2024 Q2Q % growth | -0.18 25.00% | -0.20 | 0.02 | 11.76% |
| Q2 2024 Q2Q % growth | -0.20 -33.33% | -0.16 | -0.04 | -22.55% |
| Q1 2024 Q2Q % growth | -0.19 | -0.16 | -0.03 | -16.42% |
| Q4 2023 Q2Q % growth | -0.16 11.11% | -0.16 | 0.00 | 1.96% |
| Q3 2023 Q2Q % growth | -0.24 -71.43% | -0.16 | -0.08 | -47.06% |
| Q2 2023 Q2Q % growth | -0.15 6.25% | -0.21 | 0.06 | 29.97% |
| Q1 2023 Q2Q % growth | -0.19 -11.76% | -0.21 | 0.02 | 11.30% |
| Q4 2022 Q2Q % growth | -0.18 -50.00% | -0.17 | -0.01 | -3.81% |
| Q3 2022 Q2Q % growth | -0.14 | -0.20 | 0.06 | 31.37% |
| Q2 2022 Q2Q % growth | -0.16 -14.29% | -0.19 | 0.03 | 17.44% |
| Q1 2022 Q2Q % growth | -0.17 -54.55% | -0.14 | -0.03 | -19.05% |
| Q4 2021 Q2Q % growth | -0.12 7.69% | -0.19 | 0.07 | 38.08% |
| Q3 2021 Q2Q % growth | -0.14 -40.00% | -0.18 | 0.04 | 23.75% |
| Q2 2021 Q2Q % growth | -0.14 -27.27% | -0.18 | 0.04 | 23.75% |
| Q1 2021 Q2Q % growth | -0.11 -83.33% | -0.17 | 0.06 | 36.56% |
| Q4 2020 Q2Q % growth | -0.13 -8.33% | -0.16 | 0.03 | 20.34% |
| Q3 2020 Q2Q % growth | -0.10 -100.00% | -0.14 | 0.04 | 29.97% |
| Q2 2020 Q2Q % growth | -0.11 -83.33% | -0.10 | -0.01 | -13.52% |
| Q1 2020 Q2Q % growth | -0.06 70.00% | -0.09 | 0.03 | 34.64% |
| Q4 2019 Q2Q % growth | -0.12 | -0.06 | -0.06 | -96.08% |
| Q3 2019 Q2Q % growth | -0.05 | -0.09 | 0.04 | 42.33% |
| Q2 2019 Q2Q % growth | -0.06 | -0.12 | 0.06 | 50.98% |
| Q1 2019 Q2Q % growth | -0.20 | -0.14 | -0.06 | -40.06% |
| Period | Reported | Estimate | Difference | Surprise |
|---|
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 0% | 15.79% | 26.87% | 44.94% |
| Revenue | N/A | N/A | N/A | -100% |